Introduction
dysphagia, neurodegenerative disease, tremor, cognition, mood, and sleep) signs and symptoms, synucleinopathies, constipation, Alzheimer’s disease, Parkinson’s disease, PD, rigidity
DYSPHAGIA, GASTROINTESTINAL DISORDERS, NEURODEGENERATIVE DISEASE, PATHOPHYSIOLOGY, MOTOR DISORDER, GASTROINTESTINAL DISORDERS, NEUROLOGICAL DISORDERS
Parkinson’s disease (PD) is a progressive neurodegenerative disease that mainly occurs in elderly individuals, with a global incidence of nearly 14 per 100,000. It is the most serious motor disorder and the second major neurodegenerative disease after Alzheimer’s disease,Gastrointestinal disorders, such as dysphagia and constipation, are one of the most common non-motor symptoms in PD patients.The current treatment for patients with PD is symptomatic. Doctors focus on improving motor (e.g., tremor, rigidity, and bradykinesia) and nonmotor (e.g., constipation, cognition, mood, and sleep) signs and symptoms.Recent studies have revealed that the bidirectional communication system between the brain and gut, known as the gut-brain axis, provides insight into neurological disorders’ etiology and physiology.In the past decade, it has been identified that gut microbiota can regulate the pathophysiology of synucleinopathies in PD murine model,In the present study, to reveal the efficacy and safety of FMT in improving the clinical symptoms of PD patients through oral administration (FMT capsule patent NO.: ZL201510304041.4), we performed a placebo-controlled randomized clinical trial for 54 patients with PD associated with gastrointestinal disorders. Our work provides new evidence for using FMT as an auxiliary intervention for the management of PD.